GreenLight Biosciences Acquires Bayer s topical RNA Intellectual Property portfolio
News provided by
Share this article
Share this article
BOSTON, May 20, 2021 /PRNewswire/ GreenLight Biosciences today announced that they have acquired rights to portions of Bayer s topical RNA Intellectual Property portfolio. These assets include bee health capabilities to protect against Varroa mites, a major threat to honeybees.
The RNA-based Varroa mite control advance allows beekeepers to directly target the Varroa mite without harming the honeybee, a critical advantage to other treatments on the market today.
Honeybee with parasitic Varroa destructor mite
RNA s potential for improving plant, animal, and human health has been known for years, but widespread commercial use hasn t previously been possible, due to RNA s cost of production and slow production time.
Kooperation mit Curevac: Bayer hilft bei Corona-Impfstoff ksta.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksta.de Daily Mail and Mail on Sunday newspapers.